艾普拉唑肠溶片联合克拉霉素片和呋喃唑酮片治疗老年消化性溃疡的临床研究  

Clinical trial of ilaprazole enteric-coated tablets combined with clarithromycin tablets and furazolidone tablets in the treatment of elderly peptic ulcer

作　　者：吕士红[1,2] 国向东[1,2] 李美姗[1,2] 史春静[1,2] 

机构地区：[1]牡丹江医学院第二附属医院消化内科,黑龙江牡丹江157009 [2]牡丹江医学院第二附属医院内分泌科,黑龙江牡丹江157009

出　　处：《中国临床药理学杂志》2018年第3期254-256,296,共4页The Chinese Journal of Clinical Pharmacology

基　　金：国家医学教育发展中心指导课题资助项目(2009-05-31-101)

摘　　要：目的观察艾普拉唑肠溶片联合克拉霉素片和呋喃唑酮片治疗老年消化性溃疡的临床疗效及安全性。方法将96例老年消化性溃疡患者随机分为对照组48例和试验组48例。对照组予以奥美拉唑肠溶胶囊每次40 mg,bid,口服+克拉霉素片每次0.5 g,bid,口服+呋喃唑酮片每次100 mg,qd,口服,连续治疗10 d;试验组予以艾普拉唑肠溶片每次5 mg,bid,口服+克拉霉素片每次0.5 g,bid,连续治疗5 d,之后再予以艾普拉唑肠溶片每次5 mg,bid,口服+呋喃唑酮片每次100 mg,qd,口服,连续治疗5 d。比较2组患者的临床疗效、幽门螺杆菌(Hp)阳性率、血清血管内皮细胞生长因子(VEGF)、碱性成纤维细胞生长因子(bFGF)、一氧化氮(NO)水平,以及药物不良反应的发生情况。结果治疗后,试验组和对照组的总有效率分别为95.83%(46例/48例)和72.92%(35例/48例),差异有统计学意义(P<0.05)。治疗后,试验组和对照组的Hp阳性率分别为4.17%(2例/48例)和20.83%(10例/48例),VEGF分别为(167.28±12.94)和(145.26±17.87)pg·mL^(-1),bFGF分别为(144.38±14.80)和(123.29±14.46)pg·mL^(-1),NO分别为(31.81±3.50)和(40.92±6.32)μmol·L^(-1),差异均有统计学意义(均P<0.05)。试验组发生的药物不良反应以头晕、呕吐和便秘为主,对照组发生的药物不良反应以头晕、皮疹和腹泻为主。试验组和对照组的总药物不良反应发生率分别为8.33%和16.67%,差异无统计学意义(P>0.05)。结论艾普拉唑肠溶片联合克拉霉素片和呋喃唑酮片治疗老年消化性溃疡的临床疗效确切,其能有助于调节血清VEGF、bFGF和NO的水平,且不增加药物不良反应的发生率。Objective To observe the clinical efficacy and safety of ilaprazole enteric-coated tablets combined with clarithromycin tablets and furazolidone tablets in the treatment of elderly peptic ulcer. Methods Ninety-six elderly patients with peptic ulcer were randomly divided into control and treatment groups with 48 cases per group. Control group was treated with omeprazole enteric-coated capsules 40 mg per time,bid,orally ＋ clarithromycin tablets 0. 5 g per time,bid,orally ＋ furazolidone tablets 100 mg per time,qd,orally,continuous treatment for 10 days. Treatment group was treated with ilaprazole enteric-coated tablets5 mg per time,bid,orally ＋ clarithromycin tablets 0. 5 g per time,bid,orally,continuous treatment for 5 days, then treated with ilaprazoleenteric-coated tablets 5 mg per time,bid,orally ＋ furazolidone tablet 100 mg per time,qd,orally,continuous treatment for 5 days. The clinical efficacy,Helicobacter Pylori（ Hp） positive rate,serum vascular endothelial cell growth factor（ VEGF）,basic fibroblast growth factor（ bFGF）,nitric oxide（ NO） and adverse drug reactions were compared between two groups. Results After treatment,the total effective rates of treatment and control groups were 95. 83%（ 46 cases/48 cases） and 72. 92%（ 35 cases/48 cases） with significant difference（ P〈 0. 05）. After treatment,the main indexes in treatment and control groups were compared： the Hp positive rates were 4. 17%（ 2 cases/48 cases）and 20. 83%（ 10 cases/48 cases）,the VEGF were（ 167. 28 ± 12. 94） and（ 145. 26 ± 17. 87） pg·mL^（-1）,the bFGF were（ 144. 38 ± 14. 80） and（ 123. 29 ± 14. 46） pg·mL^（-1）,the NO were（ 31. 81 ± 3. 50） and（ 40. 92 ± 6. 32）μmol·L^（-1）,the differences were statistically significant（ all P〈 0. 05）. The adverse drug reactions in the treatment group were dizziness,vomiting and constipation,which in control group were dizziness,rash and diarrhea. The total incidences of adverse drug reactions in treatment and contro

关 键 词：艾普拉唑肠溶片 克拉霉素片 呋喃唑酮片 老年 消化性溃疡 安全性 

分 类 号：R975[医药卫生—药品]